When daily IL‐2 treatment was used as part of an autologous γδT cells transfer protocol in a small group of people with advanced hematologic malignancy, 3 out of 4 achieved complete remissions lasting between 2 and 8 months.126. The gene discussed is IL2; the disease is hematologic disorder.